The HR+/HER2+ co-expressing carcinomas, so far insufficiently investigated, emerged as a group of tumors with a good response rate to neoadjuvant anthracycline/taxane chemotherapy and a favorable prognosis. The gene discussed is HR; the disease is carcinoma.